March 9, 2010
Provectus Pharmaceuticals Executes Purchase Agreements for Approximately $5.3 Million Private Placement

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) announced today that it has signed agreements with various institutional and accredited investors for the private placement of an aggregate of approximately 7.1 million shares of its convertible preferred stock and warrants to purchase approximately 3.55 million shares of its common stock at an exercise price of $1.00 per share pursuant to a Securities Purchase Agreement. The Company will receive gross proceeds of $5.3 million. The shares to be issued to the investors and the shares underlying the warrants have not been and will not be registered under the Securities Act of 1933, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Read the complete article here.

March 8, 2010
Dr. Sanjiv Agarwala to Present Update on Provectus' PV-10

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) announced today that Dr. Sanjiv Agarwala, Principal Investigator for Provectus' Phase 2 PV-10 trial site at St. Luke's Hospital & Health Network in Bethlehem, PA, will present an update on the Company's ongoing Phase 2 trial of PV-10 for metastatic melanoma at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, in New York City.

Read the complete article here.

February 9, 2010
Provectus' PV-10 and Radiotherapy Featured in Peer Reviewed Journal

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) announces the publication of an article, entitled "A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series," authored by Dr. Matthew C. Foote, Dr. Bryan H. Burmeister, Janine Thomas, and Dr. B. Mark Smithers, in the current issue of the peer-reviewed journal, Melanoma Research (20(1):48-51, February 2010).

Read the complete article here.

January 7, 2010
Provectus Pharmaceuticals Reports to Shareholders on 2009 Accomplishments and Clinical Development Plans

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) reports on its 2009 clinical and corporate accomplishments, as well as 2010 clinical development plans, in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus.

Read the complete article here.

December 1, 2009
Provectus Announces Preliminary Phase 2 Data For PH-10 in its Psoriasis and Atopic Dermatitis Trials

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) announced preliminary data for the company's PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.

Read the complete article here.

November 23, 2009
Interim Phase 2 Survival Data for PV-10 Shows Markedly Longer Overall and Disease Specific Survival for Subjects Responsive to PV-10

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data. Survival data for the Phase 1 study of PV-10 for metastatic melanoma continues to show markedly longer overall and disease specific survival for subjects that were responsive to PV-10 relative to those who did not experience a robust response. Survival data was available through early November 2009.

Read the complete article here.